PHIMC
Private Harbour Investment Management & Counsel Portfolio holdings
AUM
$96.6M
This Quarter Return
-0.9%
1 Year Return
+17.22%
3 Year Return
+74.97%
5 Year Return
+125.61%
10 Year Return
+251.19%
AUM
$114M
AUM Growth
+$114M
(-0.23%)
Cap. Flow
+$3.74M
Cap. Flow
% of AUM
3.29%
Top 10 Holdings %
Top 10 Hldgs %
42.72%
Holding
59
New
2
Increased
1
Reduced
39
Closed
3
Top Buys
| 1 |
ProShares Short QQQ
PSQ
|
$4.79M |
| 2 |
NVIDIA
NVDA
|
$2.36M |
| 3 |
DexCom
DXCM
|
$211K |
Top Sells
Sector Composition
| 1 | Healthcare | 18.78% |
| 2 | Technology | 18.5% |
| 3 | Communication Services | 8.61% |
| 4 | Consumer Staples | 7.07% |
| 5 | Consumer Discretionary | 6.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Enterprise Products Partners
EPD
$69.6B
| $353K | 0.31% |
16,290
-912
| -5% | -$19.8K |
|
52
Protolabs
PRLB
$1.19B
| $343K | 0.3% |
5,144
-4
| -0.1% | -$267 |
|
53
Newmont
NEM
$81.7B
| $329K | 0.29% |
6,060
-116
| -2% | -$6.3K |
|
54
Vanguard Tax-Exempt Bond Index Fund
VTEB
$38B
| $262K | 0.23% |
4,775
| – | – |
|
|
55
DexCom
DXCM
$29.5B
| $211K | 0.19% |
+385
| New | +$211K |
|
56
Heron Therapeutics
HRTX
$207M
| $168K | 0.15% |
15,755
-275
| -2% | -$2.93K |
|
57
Gilead Sciences
GILD
$140B
| – | – |
-24,715
| Closed | -$1.7M |
|
|
ETW
58
Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund
ETW
$977M
| – | – |
-11,425
| Closed | -$124K |
|
59
Nuveen AMT-Free Municipal Credit Income Fund
NVG
$2.53B
| – | – |
-15,548
| Closed | -$278K |
|